Markt geschlossen· · USD · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Gesamtrendite inklusive Dividenden.
Management to discuss FDA 510(k) submission, clinical data, and commercial progress outside the U.S.NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will host a virtual fireside chat on Thursday, September 24, 2026, at 4:30 p.m. ET. The moderated discussion will feature Harry Simeonidis, President and CEO, and Pet
Intelligent Bio Solutions Inc. (NASDAQ:INBS) announced on Wednesday that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) to secure regulatory clearance for its Intelligent Fingerprinting Drug Screening System. The filing focuses on detecting codeine and represents a major push to capture a share of the massive U.S. drug screening market. Extensive Clinical Evidence Drives Application To support the FDA submission, the company completed a multi-stud
Wo der Kurs im Verhältnis zu seinen 50- und 200-Tage-Durchschnitten steht.
Makkler Fair Value, Finanzgesundheit, Analystenmeinung, Vergleichsunternehmen und MakklerAI.
Submission package includes Method Comparison Study, which delivered accuracy above 98%, sensitivity above 94%, and 100% specificity across three independent U.S. clinical sitesNEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the submission of its 510(k) premarket notification to the U.S. Food and Drug Administration (FDA
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.